| 4.10 Delayed Data As of May 17 |  -0.08 / -1.91%Today’s Change | 3.22 Today|||52-Week Range 13.91 | +11.72% Year-to-Date |
| Corvus Pharmaceuticals to Present Initial Clinical Data from CPI-006 Clinical Trial a... May 16 / GlobeNewswirePNW - Paid Partner Content |
| Previous close | 4.18 |
| Today’s open | 4.11 |
| Day’s range | 4.00 - 4.18 |
| Volume | 31,486 |
| Average volume (3 months) | 85,625 |
| Market cap | $120.2M |
| Earnings growth (last year) | +37.27% |
| Earnings growth (this year) | -2.73% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.09 |
| Today’s change | Today’s % change | |
|---|---|---|
| MDWDMediwound Ltd | -0.02 | -0.45% |
| DRRXDURECT Corp | +0.00 | +0.36% |
| FBIOFortress Biotech Inc | -0.03 | -1.55% |
| TRVNTrevena Inc | +0.01 | +0.75% |
| Next reporting date | August 5, 2019 |
| EPS forecast (this quarter) | -$0.43 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$46.9M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chairman, President & Chief Executive Officer Richard A. Miller |
CFO & Principal Accounting Officer Leiv Lea |
Corporate headquarters Burlingame, California |
